AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35945477
Drug: Vasopressor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressor therapy (69% male vs 62% female)
Trial: 35945477
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy (17% male vs 11% female)
Trial: 35945477
Drug: 30-day mortality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-day mortality after adjustment for disease severity, frailty, age and treatment limitations
Trial: 35945517
Drug: PEG-rhGH 0.10-0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhGH 0.10-0.20 mg/kg/week
Trial: 35945517
Drug: PEG-rhGH 0.10-0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhGH 0.10-0.14 mg/kg/week (Group A)
Trial: 35945517
Drug: PEG-rhGH 0.15-0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhGH 0.15-0.20 mg/kg/week (Groups B, C, D)
Trial: 35945547
Drug: E7090 (tasurgratinib),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7090 (tasurgratinib), administered once daily as an oral single agent in 28-day cycles.
Trial: 35945605
Drug: Goal-directed haemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed haemodynamic therapy (GDHT) protocol based on achieving an optimal stroke volume, systolic blood pressure > 90 mmHg, and individualized cardiac index.
Trial: 35945605
Drug: Goal-directed haemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed haemodynamic therapy (GDHT) protocol
Trial: 35945605
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment (Control Group)
Trial: 35946927
Drug: Empagliflozin/linagliptin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin/linagliptin fixed-dose combination (FDC)
Trial: 35947027
Drug: Immunotherapy in
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy in the adjuvant setting
Trial: 35947027
Drug: First-in-class, highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-in-class, highly selective inhibitor of KRAS G12C
Trial: 35947087
Drug: Continuous Subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Subcutaneous Insulin Infusion
Trial: 35947435
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo MRI angiography with contrast agent injection in the umbilical cord
Trial: 35948919
Drug: Sequential epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential epirubicin and docetaxel monotherapy
Trial: 35949290
Drug: GNS561 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNS561 200 mg BID
Trial: 35949290
Drug: GNS561 50-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNS561 50-400 mg Q3W
Trial: 35949358
Drug: Tirzepatide (GIP/GLP-1R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (GIP/GLP-1R unimolecular dual agonist)
Trial: 35950205
Drug: Nilotinib 300
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 300 mg twice daily for 12 months
Trial: 35950205
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg daily after switching from nilotinib
Trial: 35950603
Drug: AdAPT-001 monotherapy
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdAPT-001 monotherapy
Trial: 35950603
Drug: AdAPT-001 combined
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdAPT-001 combined with checkpoint inhibitor
Trial: 35950621
Drug: Multikinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multikinase inhibitors
Trial: 35951553
Drug: Nominal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nominal group meetings to identify treatment goals and features
Trial: 35952709
Drug: Galunisertib 150
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib 150 mg twice daily for two 14-day courses before and during chemoradiotherapy.
Trial: 35954555
Drug: Digital Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Care Program (DCP) consisting of exercise, education, and cognitive-behavioral therapy for 8 weeks
Trial: 35957800
Drug: Antibody positive
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody positive participants
Trial: 35957800
Drug: Antibody negative
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody negative participants
Trial: 35957960
Drug: Vigil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigil (1 × 10e6-10e7 cells/dose intradermally, up to 12 doses) and durvalumab (1500 mg/dose intravenous infusion, up to 12 months)
Trial: 35958254
Drug: Fermented oyster
RxNorm normalized name: Oyster
DrugBank: Oyster (DB10550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented oyster (FO) 1,200 mg daily for 12 weeks
Trial: 35958322
Drug: Anlotinib combined
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib combined with epidermal growth factor receptor (EGFR) inhibitors in cohort A
Trial: 35958322
Drug: Anlotinib combined
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib combined with EGFR inhibitors in cohort B
Trial: 35958344
Drug: Concurrent platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent platinum-based chemoradiotherapy (CRT) followed by durvalumab maintenance treatment
Trial: 35958398
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of aspirin (150 mg/day) in high-risk patients
Trial: 35960332
Drug: Immunomodulatory five-drug
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory five-drug cocktail (IDC) + Pembrolizumab + Radiotherapy (8Gyx3)
Trial: 35962368
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate orally achieving a serum level of 0.2-0.4 mmol/l between month 6 and 12
Trial: 35963275
Drug: TB31F 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB31F 1 mg/kg intravenous
Trial: 35963275
Drug: TB31F 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB31F 3 mg/kg intravenous
Trial: 35963275
Drug: TB31F 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB31F 10 mg/kg intravenous
Trial: 35963275
Drug: TB31F (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB31F (all doses)
Trial: 35963480
Drug: FOLFOX-based adjuvant
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-based adjuvant chemotherapy
Trial: 35964116
Drug: Usability assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usability assessment of the digital health solution
Trial: 35964609
Drug: Mitapivat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitapivat (50 mg twice daily for 6 weeks, then 100 mg twice daily for 18 weeks)
Trial: 35966482
Drug: Phase-oriented trauma
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase-oriented trauma treatment for 8 weeks
Trial: 35967820
Drug: OEA (oleoylethanolamide)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Oleic monoethanolamide (DB16495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OEA (oleoylethanolamide) daily for 16 months
Trial: 35967820
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 16 months
Trial: 35968995
Drug: Early antibody-mediated
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early antibody-mediated rejection (AMR)
Trial: 35968995
Drug: Late antibody-mediated
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late antibody-mediated rejection (AMR)
Trial: 35969113
Drug: Low-milk dose
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-milk dose group
Trial: 35969451
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment as usual + educational brochures)
Trial: 35969830
Drug: Neoadjuvant nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by adjuvant nivolumab 480 mg once every four weeks (nine injections)
Trial: 35970164
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no cochlear implant)
Trial: 35970714
Drug: Alpha-1 MP
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1 MP (60 mg/kg) weekly for 52 weeks
Trial: 35970920
Drug: Individualized, heterologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA (samRNA)-based neoantigen vaccine in combination with nivolumab and ipilimumab
Trial: 35971681
Drug: Smartphone-based automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based automated insulin delivery (AID) using interoperable artificial pancreas system (iAPS) and zone model predictive control (MPC) on an unlocked smartphone for 48 hours.
Trial: 35971681
Drug: Smartphone-based automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based automated insulin delivery (AID)
Trial: 35971857
Drug: Degarelix administration
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix administration
Trial: 35971951
Drug: Bepirovirsen (75-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen (75-450 mg single dose; 150-450 mg multiple doses on days 1, 4, 8, 11, 15, and 22)
Trial: 35972667
Drug: Laparoscopic hyperthermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin/mitomycin C
Trial: 35972987
Drug: Inhaled Galectin-3
RxNorm normalized name: GALECTIN-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Galectin-3 Inhibitor
Trial: 35973031
Drug: Empagliflozin, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin, dosage and duration not available
Trial: 35973190
Drug: Sutimlimab (biweekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutimlimab (biweekly administration for a median of 20.5 weeks)
Trial: 35973199
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enasidenib with azacitidine
Trial: 35973199
Drug: Enasidenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib monotherapy after prior hypomethylating agent (HMA) therapy
Trial: 35973200
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks for up to 2 years)
Trial: 35973665
Drug: Pralsetinib 400
RxNorm normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pralsetinib 400 mg once daily until disease progression, intolerance, consent withdrawal, or investigator's decision.
Trial: 35973737
Drug: Dostarlimab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (500 mg IV every 3 weeks for 4 cycles, then 1000 mg IV every 6 weeks)
Trial: 35974320
Drug: Daily alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily alcohol consumption in the third quartile (5.36-11.42 g/day)
Trial: 35974874
Drug: Natural procreative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural procreative technology treatment
Trial: 35974896
Drug: SARS-CoV-2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibodies testing
Trial: 35975199
Drug: Multiplexed, baited,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiplexed, baited, targeted proteomics assay for detection of SARS-CoV-2 anti-spike antibody immunocomplex
Trial: 35976570
Drug: Brensocatib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib (10 mg and 25 mg)
Trial: 35976603
Drug: Esaxerenone monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaxerenone monotherapy (2.5 or 5 mg/day)
Trial: 35977532
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at 20 mg/kg/day with dose escalation to maximum tolerated dose (MTD)
Trial: 35977756
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus rucaparib (nivolumab 480 mg every 4 weeks plus rucaparib 600 mg two times per day)
Trial: 35977936
Drug: PRV111 (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRV111 (neoadjuvant treatment)
Trial: 35978403
Drug: Highest value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest value of two FIT at cutoff 10 μg Hb/g faeces
Trial: 35979039
Drug: Stimulant comorbidity
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant comorbidity
Trial: 35979886
Drug: Analytical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analytical treatment interruption (ATI) during the HIV cure-directed trial
Trial: 35980235
Drug: osilodrostat (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: osilodrostat (starting dose 2 mg bid; maximum 30 mg bid)
Trial: 35980739
Drug: Lumme Quit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumme Quit Smoking app and smartwatch combination
Trial: 35980739
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm with 8-week supply of nicotine replacement therapy, 30-minute smoking cessation counseling session, and weekly check-in calls
Trial: 35982228
Drug: Good pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good pain control under analgesic treatment
Trial: 35982228
Drug: Poor pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor pain control despite analgesic treatment
Trial: 35982244
Drug: Maternal voice
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal voice exposure (twice daily for 20 minutes before oral feeding)
Trial: 35982649
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone furoate 200 μg once daily for 14 days
Trial: 37733308
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone furoate
Trial: 35982669
Drug: Ivermectin 400
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 400 µg/kg daily for 3 days
Trial: 35983024
Drug: Apatinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (250 mg once daily) combined with docetaxel (IV every 3 weeks for four cycles) followed by epirubicin plus cyclophosphamide (IV every 3 weeks for four cycles)
Trial: 35983177
Drug: Cerene Cryotherapy
RxNorm normalized name: cedrene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerene Cryotherapy Device treatment
Trial: 35983331
Drug: mNGS-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mNGS-guided treatment
Trial: 35983331
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (guided by CMT)
Trial: 35984091
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (n = 88; 31%)
Trial: 35984091
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (control group)
Trial: 35984611
Drug: Heparin-like effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-like effect (HLE) defined as ≥ 20% difference in paired gb/h-SONOCLOT™ traces for activated clotting time (ACT)
Trial: 35986100
Drug: Alcohol/drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol/drug use
Trial: 35986671
Drug: Daily dolutegravir-abacavir-lamivudine
RxNorm normalized name: abacavir / dolutegravir / lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dolutegravir-abacavir-lamivudine
Trial: 35986823
Drug: Methylprednisolone dose
RxNorm normalized name: MethylPREDNISolone Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone dose
Trial: 35987601
Drug: Bioresorbable vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioresorbable vascular scaffold (BVS) treatment
Trial: 35987625
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment costs for malaria and pneumonia
Trial: 35987625
Drug: Timely treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely treatment for malaria and pneumonia
Trial: 35987704
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation pharmacotherapy (7.2% of current smokers)
Trial: 35988545
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after optional debulking with bendamustine
Trial: 35988546
Drug: Mitapivat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitapivat (5 mg, 20 mg, 50 mg twice daily during a 16-week dose-optimisation period followed by a 24-week fixed-dose period)
Trial: 35989865
Drug: Assessment and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment and treatment by primary care physicians
Trial: 35989865
Drug: Identification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identification of medication nonadherence
Trial: 35989865
Drug: Identification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identification of drug-drug interactions (DDIs)
Trial: 35989924
Drug: Bridging intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging intravenous thrombolysis (IVT)
Trial: 35989924
Drug: Prior medication
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior medication with Vitamin K antagonists (VKA)
Trial: 35990111
Drug: Tele-yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tele-yoga intervention (two one-on-one 30-minute sessions weekly for a total of 12 sessions)
Trial: 35992822
Drug: JMT103 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT103 at 0.5, 1.0, 2.0, and 3.0 mg/kg every 4 weeks for 3 cycles
Trial: 35992943
Drug: Contacts in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contacts in closest proximity to internal capsule
Trial: 35993306
Drug: Postneoadjuvant treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postneoadjuvant treatments (e.g., capecitabine, Olaparib)
Trial: 35993306
Drug: Type 3
RxNorm normalized name: Type 3 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 3 approaches (e.g., circulating tumour DNA)
Trial: 35994321
Drug: Active Video
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Video Game-based intervention (12 weekly sessions) with game-based pedometers, PA behavioral coaching, and survivorship navigation discussions.
Trial: 35994746
Drug: Maternal RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal RBC folate concentrations ≥906 nmol/L
Trial: 35995129
Drug: Interventions following
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions following a standard treatment algorithm for persistent cerebral desaturation.
Trial: 35995696
Drug: Autologous CIK
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CIK cells therapy combined with Sintilimab and platinum-based doublet chemotherapy
Trial: 35996565
Drug: AZD1656 (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 (100mg twice a day)